{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,16]],"date-time":"2026-05-16T15:15:52Z","timestamp":1778944552259,"version":"3.51.4"},"reference-count":20,"publisher":"Impact Journals, LLC","issue":"54","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Oncotarget"],"published-print":{"date-parts":[[2017,11,3]]},"DOI":"10.18632\/oncotarget.21579","type":"journal-article","created":{"date-parts":[[2017,10,7]],"date-time":"2017-10-07T16:18:49Z","timestamp":1507393129000},"page":"92778-92787","source":"Crossref","is-referenced-by-count":4,"title":["Concurrent administration of trastuzumab and anthracyclines as adjuvant regimen for HER2-positive breast cancer: a randomised controlled trial"],"prefix":"10.18632","volume":"8","author":[{"given":"Songjie","family":"Shen","sequence":"first","affiliation":[{"name":"Department of Breast Surgery, Peking Union Medical College Hospital, Peking Union Medical College, Chinese Academy of Medical Sciences, 1 Shuaifuyuan, Dongcheng District, Beijing 100730, China"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ying","family":"Xu","sequence":"additional","affiliation":[{"name":"Department of Breast Surgery, Peking Union Medical College Hospital, Peking Union Medical College, Chinese Academy of Medical Sciences, 1 Shuaifuyuan, Dongcheng District, Beijing 100730, China"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yidong","family":"Zhou","sequence":"additional","affiliation":[{"name":"Department of Breast Surgery, Peking Union Medical College Hospital, Peking Union Medical College, Chinese Academy of Medical Sciences, 1 Shuaifuyuan, Dongcheng District, Beijing 100730, China"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Feng","family":"Mao","sequence":"additional","affiliation":[{"name":"Department of Breast Surgery, Peking Union Medical College Hospital, Peking Union Medical College, Chinese Academy of Medical Sciences, 1 Shuaifuyuan, Dongcheng District, Beijing 100730, China"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jinghong","family":"Guan","sequence":"additional","affiliation":[{"name":"Department of Breast Surgery, Peking Union Medical College Hospital, Peking Union Medical College, Chinese Academy of Medical Sciences, 1 Shuaifuyuan, Dongcheng District, Beijing 100730, China"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Qiang","family":"Sun","sequence":"additional","affiliation":[{"name":"Department of Breast Surgery, Peking Union Medical College Hospital, Peking Union Medical College, Chinese Academy of Medical Sciences, 1 Shuaifuyuan, Dongcheng District, Beijing 100730, China"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"7892","published-online":{"date-parts":[[2017,10,6]]},"reference":[{"key":"1","doi-asserted-by":"publisher","first-page":"236","DOI":"10.1016\/S1470-2045(11)70033-X","article-title":"Treatment with trastuzumab for 1 year after adjuvant chemotherapy in patients with HER2-positive early breast cancer: a 4-year follow-up of a randomised controlled trial","volume":"12","author":"Pedrini","year":"2011","journal-title":"Lancet Oncol"},{"key":"2","doi-asserted-by":"publisher","first-page":"3366","DOI":"10.1200\/JCO.2011.35.0868","article-title":"Four-year follow-up of trastuzumab plus adjuvant chemotherapy for operable human epidermal growth factor receptor 2-positive breast cancer: joint analysis of data from NCCTG N9831 and NSABP B-31","volume":"29","author":"Wolmark","year":"2011","journal-title":"J Clin Oncol"},{"key":"3","doi-asserted-by":"publisher","first-page":"1273","DOI":"10.1056\/NEJMoa0910383","article-title":"Adjuvant trastuzumab in HER2-positive breast cancer","volume":"365","author":"Liu","year":"2011","journal-title":"N Engl J Med"},{"key":"4","doi-asserted-by":"publisher","first-page":"1530","DOI":"10.1093\/annonc\/mdn292","article-title":"Anthracycline-trastuzumab regimens for HER2\/neu-overexpressing breast cancer: current experience and future strategies","volume":"19","author":"Suter","year":"2008","journal-title":"Ann Oncol"},{"key":"5","doi-asserted-by":"crossref","first-page":"14","DOI":"10.1093\/jnci\/djm252","article-title":"HER2 status and efficacy of adjuvant anthracyclines in early breast cancer: a pooled analysis of randomized trials","volume":"100","author":"Bruzzi","year":"2008","journal-title":"J Natl Cancer Inst"},{"key":"6","doi-asserted-by":"crossref","first-page":"266","DOI":"10.1016\/S1470-2045(10)70006-1","article-title":"Predictive markers of anthracycline benefit: a prospectively planned analysis of the UK National Epirubicin Adjuvant Trial (NEAT\/BR9601)","volume":"11","author":"Pharoah","year":"2010","journal-title":"Lancet Oncol"},{"key":"7","doi-asserted-by":"publisher","first-page":"783","DOI":"10.1056\/NEJM200103153441101","article-title":"Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2","volume":"344","author":"Norton","year":"2001","journal-title":"N Engl J Med"},{"key":"8","doi-asserted-by":"crossref","first-page":"377","DOI":"10.1016\/S0140-6736(09)61964-4","article-title":"Neoadjuvant chemotherapy with trastuzumab followed by adjuvant trastuzumab versus neoadjuvant chemotherapy alone, in patients with HER2-positive locally advanced breast cancer (the NOAH trial): a randomised controlled superiority trial with a parallel HER2-negative cohort","volume":"375","author":"Ojeda","year":"2010","journal-title":"Lancet"},{"key":"9","doi-asserted-by":"crossref","first-page":"228","DOI":"10.1158\/1078-0432.CCR-06-1345","article-title":"Neoadjuvant therapy with paclitaxel followed by 5-fluorouracil, epirubicin, and cyclophosphamide chemotherapy and concurrent trastuzumab in human epidermal growth factor receptor 2-positive operable breast cancer: an update of the initial randomized study population and data of additional patients treated with the same regimen","volume":"13","author":"Symmans","year":"2007","journal-title":"Clin Cancer Res"},{"key":"10","doi-asserted-by":"publisher","first-page":"640","DOI":"10.1016\/S1470-2045(14)70080-4","article-title":"Neoadjuvant and adjuvant trastuzumab in patients with HER2-positive locally advanced breast cancer (NOAH): follow-up of a randomised controlled superiority trial with a parallel HER2-negative cohort","volume":"15","author":"Ojeda","year":"2014","journal-title":"Lancet Oncol"},{"key":"11","doi-asserted-by":"publisher","first-page":"1317","DOI":"10.1016\/S1470-2045(13)70502-3","article-title":"Fluorouracil, epirubicin, and cyclophosphamide (FEC-75) followed by paclitaxel plus trastuzumab versus paclitaxel plus trastuzumab followed by FEC-75 plus trastuzumab as neoadjuvant treatment for patients with HER2-positive breast cancer (Z1041): a randomised, controlled, phase 3 trial","volume":"14","author":"Hunt","year":"2013","journal-title":"Lancet Oncol"},{"key":"12","doi-asserted-by":"crossref","first-page":"4491","DOI":"10.1200\/JCO.2011.36.7045","article-title":"Sequential versus concurrent trastuzumab in adjuvant chemotherapy for breast cancer","volume":"29","author":"Jenkins","year":"2011","journal-title":"J Clin Oncol"},{"key":"13","doi-asserted-by":"publisher","first-page":"2416","DOI":"10.1200\/JCO.2016.67.0182","article-title":"Selection of optimal adjuvant chemotherapy regimens for human epidermal growth factor receptor 2 (HER2) -negative and adjuvant targeted therapy for HER2-positive breast cancers: An American Society of Clinical Oncology Guideline Adaptation of the Cancer Care Ontario Clinical Practice Guideline","volume":"34","author":"Wolff","year":"2016","journal-title":"J Clin Oncol"},{"key":"14","doi-asserted-by":"publisher","first-page":"46","DOI":"10.1159\/000358754","article-title":"Cardiac tolerability of concurrent administration of trastuzumab and anthracycline-based regimen as adjuvant chemotherapy for breast cancer","volume":"9","author":"Uchino","year":"2014","journal-title":"Breast Care (Basel)"},{"key":"15","doi-asserted-by":"publisher","first-page":"253","DOI":"10.3233\/BD-150418","article-title":"Retrospective analysis of cardiac tolerability of concurrent administration of trastuzumab and anthracycline-based regimen for breast cancer, to address one-year-term issues in LVEF","volume":"35","author":"Shimada","year":"2015","journal-title":"Breast Dis"},{"key":"16","doi-asserted-by":"publisher","first-page":"3792","DOI":"10.1200\/JCO.2011.40.0010","article-title":"Seven-year follow-up assessment of cardiac function in NSABP B-31, a randomized trial comparing doxorubicin and cyclophosphamide followed by paclitaxel (ACP) with ACP plus trastuzumab as adjuvant therapy for patients with node-positive, human epidermal growth factor receptor 2-positive breast cancer","volume":"30","author":"Polikoff","year":"2012","journal-title":"J Clin Oncol"},{"key":"17","doi-asserted-by":"publisher","first-page":"2024","DOI":"10.1016\/j.ejca.2007.07.008","article-title":"The anthracycline-trastuzumab interaction: up-regulated binding may provide vital mechanistic insight","volume":"43","author":"Ewer","year":"2007","journal-title":"Eur J Cancer"},{"key":"18","doi-asserted-by":"crossref","first-page":"2900","DOI":"10.1200\/JCO.2005.05.827","article-title":"Type II chemotherapy-related cardiac dysfunction: time to recognize a new entity","volume":"23","author":"Lippman","year":"2005","journal-title":"J Clin Oncol"},{"key":"19","doi-asserted-by":"crossref","first-page":"839","DOI":"10.1016\/S0002-9440(10)64952-8","article-title":"Amplification and deletion of topoisomerase IIalpha associate with ErbB-2 amplification and affect sensitivity to topoisomerase II inhibitor doxorubicin in breast cancer","volume":"156","author":"Isola","year":"2000","journal-title":"Am J Pathol"},{"key":"20","doi-asserted-by":"publisher","first-page":"2241","DOI":"10.1038\/sj.onc.1202526","article-title":"Inhibitory effects of combinations of HER-2\/neu antibody and chemotherapeutic agents used for treatment of human breast cancers","volume":"18","author":"Slamon","year":"1999","journal-title":"Oncogene"}],"container-title":["Oncotarget"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.oncotarget.com\/lookup\/doi\/10.18632\/oncotarget.21579","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,8,6]],"date-time":"2020-08-06T18:20:40Z","timestamp":1596738040000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.oncotarget.com\/lookup\/doi\/10.18632\/oncotarget.21579"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2017,10,6]]},"references-count":20,"journal-issue":{"issue":"54","published-print":{"date-parts":[[2017,11,3]]}},"alternative-id":["21579","29190955"],"URL":"https:\/\/doi.org\/10.18632\/oncotarget.21579","relation":{},"ISSN":["1949-2553"],"issn-type":[{"value":"1949-2553","type":"electronic"}],"subject":[],"published":{"date-parts":[[2017,10,6]]}}}